NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. manufactures and sells wound care products. The company offers hypochlorous acid for use in the cleansing and irrigation of post-surgical wounds, minor burns, and superficial abrasions. It sells its products to its distribution partners in China. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in F… Read more
Market Cap & Net Worth: NovaBay Pharmaceuticals Inc (NBY)
NovaBay Pharmaceuticals Inc (NYSE MKT:NBY) has a market capitalization of $33.44 Million ($33.44 Million) as of March 19, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #33440 globally and #10927 in its home market, demonstrating a 1.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NovaBay Pharmaceuticals Inc's stock price $1.28 by its total outstanding shares 26124680 (26.12 Million).
NovaBay Pharmaceuticals Inc Market Cap History: 2015 to 2026
NovaBay Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $64.65 Billion to $33.44 Million (-57.98% CAGR).
NovaBay Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NovaBay Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.61x
NovaBay Pharmaceuticals Inc's market cap is 1.61 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $64.65 Billion | $4.38 Million | -$18.97 Million | 14755.88x | N/A |
| 2016 | $105.61 Billion | $11.90 Million | -$13.15 Million | 8876.95x | N/A |
| 2017 | $123.21 Billion | $18.23 Million | -$7.40 Million | 6758.67x | N/A |
| 2018 | $24.73 Billion | $12.51 Million | -$6.54 Million | 1977.02x | N/A |
| 2019 | $20.48 Billion | $6.60 Million | -$9.66 Million | 3103.77x | N/A |
| 2020 | $22.31 Billion | $9.93 Million | -$11.04 Million | 2245.41x | N/A |
| 2021 | $12.05 Billion | $10.20 Million | -$5.82 Million | 1181.13x | N/A |
| 2022 | $1.78 Billion | $14.40 Million | -$10.61 Million | 123.79x | N/A |
| 2023 | $186.53 Million | $10.46 Million | -$9.64 Million | 17.84x | N/A |
| 2024 | $15.70 Million | $9.78 Million | -$7.22 Million | 1.61x | N/A |
Competitor Companies of NBY by Market Capitalization
Companies near NovaBay Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to NovaBay Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NovaBay Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, NovaBay Pharmaceuticals Inc's market cap moved from $64.65 Billion to $ 33.44 Million, with a yearly change of -57.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $33.44 Million | -77.30% |
| 2025 | $147.34 Million | +838.44% |
| 2024 | $15.70 Million | -91.58% |
| 2023 | $186.53 Million | -89.54% |
| 2022 | $1.78 Billion | -85.21% |
| 2021 | $12.05 Billion | -45.97% |
| 2020 | $22.31 Billion | +8.91% |
| 2019 | $20.48 Billion | -17.17% |
| 2018 | $24.73 Billion | -79.93% |
| 2017 | $123.21 Billion | +16.67% |
| 2016 | $105.61 Billion | +63.37% |
| 2015 | $64.65 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of NovaBay Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $33.44 Million USD |
| MoneyControl | $33.44 Million USD |
| MarketWatch | $33.44 Million USD |
| marketcap.company | $33.44 Million USD |
| Reuters | $33.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.